Phase 1 · NCT05611957
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
A Parallel-group, Phase 1, Open-label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Renal Impairment Compared With Healthy Participants
CompletedVerified
Registry record
Trial details
- Trial
- A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
- ClinicalTrials.gov ID
- NCT05611957
- Indication
- Healthy, Renal Insufficiency
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 29
- Status
- Completed
- Interventions
- Drug: LY3437943
- Comparator
- Not reported
- Eligible ages
- 18 Years – 85 Years
- Locations
- 4 sites · United States
- Study start
- 16 Nov 2022
- Primary completion
- 5 Sept 2023
- Study completion
- 5 Sept 2023
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 2 Oct 2023
Endpoints
Primary
Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943; PK: Maximum observed concentration (Cmax) of LY3437943